Video Experimental Relacionado

Updated: Mar 2, 2026

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells

Published on: August 1, 2025

Sistemas de administración de nanfármacos en inmunoterapia tumoral: de la activación inmune a la reprogramación

Dengxuan Mao¹, Bingqian Li¹, Jing Li¹

¹School of pharmacy, Shanghai University of Traditional Chinese Medicine, Pudong New Area, Shanghai, 201203, China.

Advanced drug delivery reviews

|February 28, 2026

Resumen

Los sistemas de administración de nanfármacos (NDDS) están evolucionando de portadores de fármacos a amplificadores inmunes en la terapia contra el cáncer. Estos sistemas mejoran la inmunoterapia contra el cáncer al activar las células inmunes y remodelar el microambiente tumoral para obtener respuestas de memoria duraderas.

Sus antecedentes:

Los sistemas de administración de nanfármacos (NDDS) ofrecen ventajas en la distribución, el direccionamiento y la biodisponibilidad de fármacos para la inmunoterapia tumoral.
Los NDDS son cada vez más reconocidos por su papel en la activación inmune, incluida la inducción de muerte celular inmunogénica (ICD) y la modulación de células inmunes.
Las plataformas de nanomateriales están pasando de ser simples portadores de fármacos a amplificadores inmunes activos.

Conclusiones:

Los NDDS representan una frontera prometedora en la inmunoterapia contra el cáncer, actuando como potentes amplificadores inmunes.
El diseño inteligente de los NDDS es crucial para optimizar las respuestas sinérgicas entre la inmunidad innata y adaptativa.
La investigación adicional sobre estrategias impulsadas por IA y la superación de los desafíos actuales avanzarán la inmunoterapia de precisión contra el cáncer.

Palabras clave:

Sistemas de administración de fármacos Nanopartículas Inmunoterapia tumoral

Más Videos Relacionados

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

Videos de Conceptos Relacionados

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Modified-Release Drug Delivery Systems: Site-Targeted

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Modified-Release Drug Delivery Systems: Stimuli-Activated

Modified-Release Drug Delivery Systems: Stimuli-Activated

Stimuli-activated drug delivery systems are designed to release drugs in response to specific physical, chemical, or biological stimuli. These systems often utilize hydrogels—three-dimensional, hydrophilic polymer networks capable of swelling in aqueous environments and retaining significant fluid volumes. Upon exposure to particular stimuli, these hydrogels undergo structural transitions that allow the embedded drug to be released. Due to this adaptive behavior, such systems are also...

The Tumor Microenvironment

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...